Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification

References

• Schaeffler AJ. Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med 2006;355:1690–8.
   PubMedGoogle Scholar
• Krieger JN, Nyberg LJr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;281:236–7.
   Google Scholar
• Kim SH, Jung KI, Koh JS, Min KO, Cho SY, Kim HW. Lower urinary tract symptoms in benign prostatic hyperplasia patients: orchestrated by chronic prostatic inflammation and prostatic calculi? Urol Int 2013;90:144–9.
   PubMed Web of Science ®Google Scholar
• Shoskes DA, Lee CT, Murphy D, Kefer J, Wood HM. Incidence and significance of prostatic stones in men with chronic prostatitis/chronic pelvic pain syndrome. Urology 2007;70:235–8.
   PubMed Web of Science ®Google Scholar
• Park SW, Nam JK, Lee SD, Chung MK. Are prostatic calculi independent predictive factors of lower urinary tract symptoms? Asian J Androl 2010;12:221–6.
   PubMed Web of Science ®Google Scholar
• Kim WB, Doo SW, Yang WJ, Song YS. Influence of prostatic calculi on lower urinary tract symptoms in middle-aged men. Urology 2011;78:447–9.
   PubMed Web of Science ®Google Scholar
• Zhao WP, Li YT, Chen J, Zhang ZG, Jiang H, Xia D, et al. Prostatic calculi influence the antimicrobial efficacy in men with chronic bacterial prostatitis. Asian J Androl 2012;14:715–19.
   PubMed Web of Science ®Google Scholar
• Hwang EC, Choi HS, Im CM, Jung SI, Kim SO, Kang TW, et al. Prostate calculi in cancer and BPH in a cohort of Korean men: presence of calculi did not correlate with cancer risk. Asian J Androl 2010;12:215–20.
   PubMed Web of Science ®Google Scholar
• Eykyn S, Builitude MI, Mayo ME, Looyd-Davis RW. Prostatic calculi as a source of recurrent bacteruria in the male. Br J Urol 1974;46:527–32.
   PubMedGoogle Scholar
• Meares EM. Infection stones of prostatic gland. Laboratory diagnosis and clinical management. Urology 1974;4:560–6.
   PubMedGoogle Scholar
• Cross PA, Bartley CJ, McClure J. Amyloid in prostatic corpora amylacea. J Clin Pathol 1992;45:894–7.
   PubMed Web of Science ®Google Scholar
• McNaughton CO, Wilt T. Allopurinol for chronic prostatitis. Cochrane Database Syst Rev 2002;(4): CD001041.
   Google Scholar
• Sfanos KS, Wilson BA, De Marzo AM, Isaacs WB. Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. Proc Natl Acad Sci USA 2009;106:3443–8.
   PubMed Web of Science ®Google Scholar
• Engelhardt PF, Seklehner S, Brustmann H, Lusuardi L, Riedl CR. Immunohistochemical expression of interleukin-2 receptor and interleukin-6 expression in patients with prostate cancer and benign prostate hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV. Scand J Urol 2015;49:120–6.
   Web of Science ®Google Scholar
• Old LJ. Tumor necrosis factor alpha (TNF). Science 1985;230:630–2.
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987;330:662–4.
   PubMed Web of Science ®Google Scholar
• Spillmann F, Van Linthout S, Miteva K, Lorenz M, Stangl V, Schultheiss HP, et al. LXR agonism improves TNF-α-induced endothelial dysfunction in the absence of is cholesterol-modulating effects. Atherosclerosis 2014;232:1–9.
   PubMed Web of Science ®Google Scholar
• Calabrese F, Carturan E, Chimenti C, Pieroni M, Agostini C, Angelini A, et al. Overexpression of tumor necrosis factor (TNF)α and TNF-α receptor I in human viral myocarditis: clinicopathologic correlations. Mod Pathol 2004;17:1108–18.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Matsumoto I, Iwanami K, Inoue A, Umeda N, Tanaka Y, et al. Six-transmembrane epithelial antigen of prostate 4 (STEAP4) is expressed on monocytes/neutrophils, and is regulated by TNF antagonist in patients with rheumatoid arthritis. Clin Exp Rheumatol 2012;30:99–102.
   PubMed Web of Science ®Google Scholar
• Castiglione R, Salemi M, Vicari LO, Vicari E. Relationship of semen hyperviscosity with IL-6, TNF-α, IL-10 and ROS production in seminal plasma of infertile patients with prostatitis and prostato-vesiculitis. Andrologia 2014;46:1148–55.
   PubMed Web of Science ®Google Scholar
• Alexander RB, Ponniah S, Hasday J, Hebel JR. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology 1998;52:744–9.
   PubMed Web of Science ®Google Scholar
• He l, Wang Y, Long Z, Jiang C. Clinical significance of IL-2, IL-10 and TNF-α in prostatic secretion of patients with chronic prostatitis. Urology 2010;75:654–7.
   PubMed Web of Science ®Google Scholar
• Rosen RC, Riley A, Wagner G, Osterloh JH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822–30.
   PubMed Web of Science ®Google Scholar
• Litwin MS, McNaughton-Collins M, Flowler FJJr, Nickel JC, Calhoun EA, Pontari MA, et al. The NIH Chronic Prostatitis Index [NIH-CPSI]: development and validation of a new outcome measure. J Urol 1999;162:369–75.
   PubMed Web of Science ®Google Scholar
• Irani J, Levillian P, Gouion JM, Bon D, Dore B, Aubert J. Inflammation in benign prostatic hyperplasia: correlation with prostatic specific antigen value. J Urol 1997;157:1301–3.
   PubMed Web of Science ®Google Scholar
• Sciarra A, Di Silverio F, Salciccia S, Gomez AAG, Gentilucci A, Gentile V. Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 2007;52:964–72.
   PubMed Web of Science ®Google Scholar
• De Nunzio C, Kramer G, Marberger M, Nelson W, Schröder F, Sciarra A, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011;60:106–17.
   PubMed Web of Science ®Google Scholar
• Goldstraw MA, Fitzpatrick JM, Kirby RS. What is the role of inflammation in the pathogenesis of prostate cancer? BJU Int 2007;15:1–2.
   Google Scholar
• Nickel JG. Prostatic inflammation in BPH: the third component? Can J Urol 1994;1:1–4.
   PubMedGoogle Scholar
• Engelhardt PF, Brustmann H, Seklehner S, Riedl CR. Chronic asymptomatic inflammation of the prostate type IV and carcinoma of the prostate: is there a correlation? Scand J Urol 2013;47:230–5.
   Web of Science ®Google Scholar
• Lee SE, Ku JH, Park HK, Jeong CK, Kim SH. Prostatic calculi do not influence the level of serum prostate specific antigen in men without clinically detectable prostate cancer or prostatitis. J Urol 2003;170:745–8.
   PubMed Web of Science ®Google Scholar
• Hammarsten J, Högstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999;8:29–36.
   PubMed Web of Science ®Google Scholar
• Gradolatto A, Nazzal D, Truffault F, Bismuth J, Fadal E, Foti M, et al. Both Treg cells and Tconv cells are defective in the myasthenia gravis thymus: roles of IL-17 and TNF-α. J Autoimmun 2014;52:53–63.
   PubMed Web of Science ®Google Scholar
• Shimada O, Wu X, Nouh MA, Fiscella M, Albert V, Matsuda T, et al. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells. Urology 2007;69:295–401.
   PubMedGoogle Scholar
• Zhang X, Li W, Olumi AF. Low-dose 12-O-tertadecanoylphobrol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells. Clin Cancer Res 2007;13:7181–90.
   PubMed Web of Science ®Google Scholar
• Festuccia C, Gravina GL, D’Alessandro AM, Millimaggi D, Di Rocco C, Dolo V. Down modulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells. Int J Oncol 2008;33:381–8.
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Kumar R, Koduro S, Chandramouli A, Damodaran C. Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent prostate cancer. Apoptosis 2010;15:153–61.
   PubMed Web of Science ®Google Scholar
• Tsunemori H, Sugimoto M, Xia Z, Taoka R, Oka M, Kakehi Y. Effect of the phytotherapeutic agent Eviprostat on inflammatory changes and cytokine production in a rat model on nonbacterial prostatitis. Urology 2011;77:1507.e15–20.
   PubMedGoogle Scholar